Skip to main content
Livermore
Livermore
ZHEN

VR Adviser, LLC

SEC CIK
0001615982
Latest filing
Aug 14, 2026

Holdings in Q4 2023

Holdings as of Dec 31, 2023, filed Feb 14, 2024. Long positions only; changes compare share counts with Q3 2023.

Institution overview
Positions
36
−1 vs. Q3 2023
Portfolio value
$1.46B
+$508.1M (+53.5%) vs. Q3 2023
Filed
Feb 14, 2024
SEC
Holdings of VR Adviser, LLC in Q4 2023
SecurityClassSharesValue% of portfolioShare changeActionHistory
OLMAOlema Pharmaceuticals, Inc.COM77,042$1.08M0.1%00.0%UnchangedHistory
MISTMilestone Pharmaceuticals Inc.COM925,048$1.54M0.1%−1,283,764−58.1%ReducedHistory
ADVMAdverum Biotechnologies, Inc.COM5,147,547$3.88M0.3%−1,425,753−21.7%ReducedHistory
TRVITrevi Therapeutics, Inc.COM3,422,397$4.59M0.3%00.0%UnchangedHistory
EYPTEyePoint, Inc.COM NEW250,000$5.78M0.4%+250,000NewHistory
SLRNACELYRIN, Inc.COM937,113$6.99M0.5%+72,781+8.4%AddedHistory
GHRSGH Research PLCORDINARY SHARES1,318,327$7.65M0.5%−1,425,798−52.0%ReducedHistory
PRAXPraxis Precision Medicines, Inc.COM NEW353,626$7.88M0.5%00.0%UnchangedConverted for a 1-for-15 splitHistory
DNTHDianthus Therapeutics, Inc.COM927,706$9.65M0.7%00.0%UnchangedHistory
ABVXAbivax S.A.SPONSORED ADS998,570$10.7M0.7%+998,570NewHistory
LYRALyra Therapeutics, Inc.COM2,575,593$13.5M0.9%+1,651,423+178.7%AddedHistory
SVRASavara IncCOM3,500,000$16.4M1.1%−3,684,865−51.3%ReducedHistory
TSHATaysha Gene Therapies, Inc.COM SHS10,412,872$18.4M1.3%−4,031,572−27.9%ReducedHistory
APLTApplied Therapeutics, Inc.COM6,250,000$20.9M1.4%+591,966+10.5%AddedHistory
ORICOric Pharmaceuticals, Inc.COM2,428,385$22.3M1.5%+285,529+13.3%AddedHistory
RYTMRhythm Pharmaceuticals, Inc.COM495,983$22.8M1.6%−594,017−54.5%ReducedHistory
ATXSAstria Therapeutics, Inc.COM3,225,806$24.8M1.7%+3,225,806NewHistory
ARVNArvinas, Inc.COM627,788$25.8M1.8%+627,788NewHistory
MRSNMersana Therapeutics, Inc.COM11,328,000$26.3M1.8%00.0%UnchangedHistory
CELCCelcuity Inc.COM1,885,538$27.5M1.9%−219,848−10.4%ReducedHistory
COGTCogent Biosciences, Inc.COM4,684,167$27.5M1.9%00.0%UnchangedHistory
DYNDyne Therapeutics, Inc.COM2,173,913$28.9M2.0%00.0%UnchangedHistory
TERNTerns Pharmaceuticals, Inc.COM4,497,117$29.2M2.0%+1,404,844+45.4%AddedHistory
AMAMAmbrx Biopharma, Inc.COM2,070,000$29.5M2.0%00.0%UnchangedHistory
HLVXHilleVax, Inc.COM2,075,000$33.3M2.3%+37,687+1.8%AddedHistory
OCULOcular Therapeutix, IncCOM7,775,760$34.7M2.4%+7,775,760NewHistory
ELVNEnliven Therapeutics, Inc.COM2,954,902$40.9M2.8%00.0%UnchangedHistory
KALVKalVista Pharmaceuticals, Inc.COM4,092,731$50.1M3.4%+1,176,064+40.3%AddedHistory
SYRESpyre Therapeutics, Inc.COM NEW2,372,714$51.1M3.5%+2,372,714NewHistory
CABACabaletta Bio, Inc.COM2,563,952$58.2M4.0%+590,699+29.9%AddedHistory
MRUSMerus N.V.COM2,148,214$59.1M4.1%+422,000+24.4%AddedHistory
FDMT4D Molecular Therapeutics, Inc.COM3,424,031$69.4M4.8%+424,031+14.1%AddedHistory
VRDNViridian Therapeutics, Inc.COM3,882,623$84.6M5.8%+800,001+26.0%AddedHistory
PHVSPharvaris N.V.COM3,395,606$95.2M6.5%+1,832,093+117.2%AddedHistory
APGEApogee Therapeutics, Inc.COM8,493,321$237.3M16.3%00.0%UnchangedHistory
RYZBRayzeBio, Inc.COM4,030,471$250.6M17.2%+13,624+0.3%AddedHistory

Sold out since Q3 2023 (7)

Positions held at the end of Q3 2023 that are gone from this filing.

Positions of VR Adviser, LLC sold out since Q3 2023
SecurityClassShares in Q3 2023Value in Q3 2023% of portfolio in Q3 2023History
TVTXTravere Therapeutics, Inc.COM2,623,677$23.5M2.5%History
ACRSAclaris Therapeutics, Inc.COM1,040,754$7.13M0.8%History
PLRXPliant Therapeutics, Inc.COM288,949$5.01M0.5%History
SGMTSagimet Biosciences Inc.COM SER A515,000$4.53M0.5%History
SYRESpyre Therapeutics, Inc.COM295,034$3.61M0.4%History
RLYBRallybio CorpCOM268,532$905.0K0.1%History
Affimed N VN01045108COM1,428,571$682.7K0.1%–